NCT06847204

EFFICACY OF COLCHICINE IN IMPROVING CLINICAL OUTCOMES IN PATIENTS WITH MILD TO MODERATE COVID-19 PNEUMONIA IN LAHORE: A RANDOMIZED CONTROL TRIAL

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: Zaeema Kanwal · Other Government
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This study is for patients suffering from COVID-19 pneumonia (mild to moderate cases) ; especially in developing countries where expensive drugs are not available. Colchicine is an economically favourable anti inflammatory drug readily Used for gout patients but is being given experimentally in Covid 19 patients . Study has been designed in this way that drug has been given carefully to patients on which there will be no to minimum side effects . It is only to see beneficial effects if any present in Covid pneumonia patients which will be observed by clinical \& lab improvement.

Detailed description

Colchicine, an anti-inflammatory drug used conventionally to treat gout and pericarditis. This study shows effectiveness of colchicine in enhancing clinical outcomes in mildly to moderately severe COVID-19 pneumonia patients. Improvement will be observed in terms of shorter hospital admissions and oxygen dependency .

Conditions

• COVID - 19

Interventions

Type	Name	Description
DRUG	Colchicine 0.5 MG Oral Tablet	Colchicine is anti inflammatory drug which will be given to Covid pneumonia patients and their benefit will be observed in them

Timeline

• Start date: 2025-02-24
• Primary completion: 2025-05-30
• Completion: 2025-06-24
• First posted: 2025-02-26
• Last updated: 2025-09-04

Locations

1 site across 1 country: Pakistan